{"schema_version":"secwatch.filing_event.v1","accession":"0001171843-25-006316","form_type":"8-K","ticker":"ABUS","cik":"0001447028","company_name":"Arbutus Biopharma Corp","filed_at":"2025-10-07T23:59:59+00:00","discovered_at":"2026-05-14T18:02:39.431206+00:00","generated_at":"2026-05-17T04:25:39.747819+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"confidence":"high","headline":"Arbutus announces four abstracts accepted for AASLD, including AB-101 Poster of Distinction","bullets":["Three abstracts on imdusiran and one on AB-101 accepted for AASLD Liver Meeting Nov 7-11, 2025 in Washington DC.","Imdusiran integrated safety analysis shows well-tolerated at 60-90 mg Q8W for up to 48 weeks dosing and follow-up.","Imdusiran may enhance pegylated interferon responsiveness in HBV genotype B/C patients vs historical data.","AB-101 up to 30 mg QD for 28 days was well tolerated; 83% mean PD-L1 receptor occupancy at 30 mg dose.","AB-101 abstract selected as Poster of Distinction; data on safety, PK, PD and HBV biomarkers will be presented."],"urls":{"canonical":"https://secwatch.observer/filing/0001171843-25-006316","json":"https://secwatch.observer/filing/0001171843-25-006316.json","markdown":"https://secwatch.observer/filing/0001171843-25-006316.md","text":"https://secwatch.observer/filing/0001171843-25-006316.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1447028/000117184325006316/0001171843-25-006316-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1447028/000117184325006316/f8k_100625.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T04:25:39.747819+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}